- Parataxis Holdings will take a controlling stake in Bridge Biotherapeutics.
- The company will be renamed Parataxis Korea and focus on Bitcoin treasury strategies.
- This marks the first institutional BTC treasury firm listed in South Korea.
Parataxis Holdings has announced a major step into South Korea’s public market. The New York-based digital asset firm will acquire a controlling stake in Bridge Biotherapeutics through a KRW 25 billion investment. The transaction will take place via its affiliate, Parataxis Korea Fund I LLC.
NEW: 🇰🇷 Parataxis Holdings acquires biotech firm Bridge Biotherapeutics to establish Parataxis Korea.
— Roxom TV (@RoxomTV) June 20, 2025
They will set up a "#Bitcoin-native treasury platform" – modeled after Strategy and Metaplanet. 🔥 pic.twitter.com/NWjx8SXjUH
After completion, the company will hence be referred to as Parataxis Korea but still maintains its previous listing on the KOSDAQ stock exchange. The deal between the two companies is still pending shareholder approval as well as other standard closing requirements.
With this acquisition, it is hoped to create South Korea’s first Bitcoin-native treasury platform within the public market. Parataxis wishes to model what has happened in the U.S. and Japan when some listed firms have chosen to secure their Bitcoin on their balance sheets for the long-term future.
Edward Chin Joins Parataxis Company Board
The company will receive support from players in the industry knowledgeable about digital assets. Parataxis designed the structure to offer Bitcoin exposure through corporate equity, especially for regulated investors or those with higher risk appetites.
Parataxis in this transaction aims to combine the biotech operations with a modern financial approach that is based on bitcoin. It regards South Korea as a logical beginning for this strategy due to its technological infrastructure and active retail crypto interest.
In compliance with the agreement, leadership at the company will also change. Parataxis Capital will appoint partner Andrew Kim as CEO. Parataxis Holdings President Edward Chin, or a chosen appointee, will join the board of directors. James Jungkue Lee, a co-founder of Bridge Biotherapeutics at that time, shall remain as director and carry on in charge of their biotech operations
Parataxis Plans Bitcoin-Backed Growth Strategy
Parataxis aims at wise capital management while striving to develop with the help of Bitcoin, which is their primary reserve currency. The company is adapting its position in order to preserve shareholders’ value for the long term by means of digital asset management in addition to its core business.
In addition to the deal, Parataxis Holdings is raising funds for another vehicle with a similar strategy. It also intends to launch more vehicles in line with its vision. The company will hold an investors meeting in August to discuss further details so that they can share their plans later on.
Shin & Kim LLC provides legal counsel in the transaction, while Deloitte is the financial advisor. They direct the process, as both firms are doing so by setting a new precedent for BTC-driven corporate strategy in the S. Korean market.
Related Reading: Bitcoin’s Uncertainty: Will Market Signals Lead to a Major Price Move?
How would you rate your experience?